Inventor
WENDT DANIEL J
US24 patents
⚠️ This page may combine multiple inventors who share the name “WENDT DANIEL J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BIOMARIN PHARM INC
21 patentsUS7534595B2May 19, 2009
Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
BIOMARIN PHARM INC79 citations96
US7537923B2May 26, 2009
Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
BIOMARIN PHARM INC49 citations95
US7790433B2Sep 7, 2010
Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
BIOMARIN PHARM INC32 citations91
US8377884B2Feb 19, 2013
Variants of C-type natriuretic peptides
BIOMARIN PHARM INC27 citations88
US10301369B2May 28, 2019
Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteins
BIOMARIN PHARM INC5 citations83
US9845346B2Dec 19, 2017
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
BIOMARIN PHARM INC4 citations83
US9834588B2Dec 5, 2017
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
BIOMARIN PHARM INC7 citations83
US9834587B2Dec 5, 2017
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
BIOMARIN PHARM INC6 citations83
US9771408B2Sep 26, 2017
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
BIOMARIN PHARM INC4 citations83
US9376480B2Jun 28, 2016
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
BIOMARIN PHARM INC6 citations83
US10646550B2May 12, 2020
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
BIOMARIN PHARM INC7 citations82
US11254725B2Feb 22, 2022
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
BIOMARIN PHARM INC2 citations72
USRE48267EOct 20, 2020
Variants of C-type natriuretic peptide
BIOMARIN PHARM INC2 citations72
US9907834B2Mar 6, 2018
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
BIOMARIN PHARM INC3 citations71
US10221408B2Mar 5, 2019
Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
BIOMARIN PHARM INC3 citations69
US12514906B2Jan 6, 2026
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
BIOMARIN PHARM INC0 citations60
US12076372B2Sep 3, 2024
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
BIOMARIN PHARM INC0 citations60
US11911446B2Feb 27, 2024
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
BIOMARIN PHARM INC0 citations60
US11590204B2Feb 28, 2023
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
BIOMARIN PHARM INC0 citations60
US11505790B2Nov 22, 2022
Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
BIOMARIN PHARM INC1 citations58
USRE46707EFeb 13, 2018
Variants of C-type natriuretic peptide
BIOMARIN PHARM INC0 citations51